Health Strategies Group Key Finding #1 12/8/2018 Health Strategies Group Author/Artist Evolving Market Dynamics Will Continue to Influence Use of Oncology Drugs by 2019 Availability of new brands, emerging drug classes, and potential entrance of biosimilars may compel stakeholders to increase utilization management tactics, narrowing selection of preferred treatments. Biopharmaceutical companies that support stakeholder objectives of achieving high-quality, cost- effective long-term care for oncology patients will benefit from improved relations and likely sustain optimal access for their brands. To request slides info@healthstrategies.com